Kolon TissueGene, Inc. is a biopharmaceutical company, which engages in the development of clinical-stage cell therapies for osteoarthritis. It offers TG-C, a platform technology that consists of a combination of allogeneic primary cells combined with genetically modified cells. The company was founded by Kwan H. Lee on June 9, 1999 and is headquartered in Rockville, MD.